Haemonetics Corporation (NYSE:HAE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $83.8889.

HAE has been the topic of a number of research reports. Mizuho lowered their price target on Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. Robert W. Baird set a $81.00 price objective on Haemonetics in a research note on Friday, February 6th. Citigroup decreased their price objective on Haemonetics from $75.00 to $70.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, Barrington Research set a $94.00 price target on Haemonetics in a research note on Friday, February 6th.

Hedge Funds Weigh In On Haemonetics

A number of large investors have recently bought and sold shares of the company. Central Pacific Bank Trust Division lifted its stake in shares of Haemonetics by 2.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock worth $713,000 after acquiring an additional 188 shares during the period. Quantinno Capital Management LP increased its stake in shares of Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after acquiring an additional 289 shares during the period. UMB Bank n.a. raised its holdings in Haemonetics by 110.9% during the fourth quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 306 shares in the last quarter. Cardinal Capital Management raised its holdings in Haemonetics by 1.5% during the fourth quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock worth $1,799,000 after purchasing an additional 321 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in Haemonetics in the fourth quarter valued at about $26,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 0.7%

NYSE:HAE opened at $59.93 on Monday. The stock’s 50 day moving average price is $66.67 and its 200 day moving average price is $64.79. The company has a market capitalization of $2.78 billion, a PE ratio of 16.51, a P/E/G ratio of 1.25 and a beta of 0.28. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The company had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts anticipate that Haemonetics will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.